Many of the traders I talk to are wondering what Bill Ackman could be thinking. Ackman is a hedge fund manager, the founder and CEO of Pershing Square Capital Management, which has about $11 billion under management. Ackman is considered a contrarian investor who tends to buy when companies are down, and an activist investor who sometimes takes a role in managing companies he invests in. He has achieved incredible success by some measures and has a reported wealth of about $1.4 billion. Ackman recently shared a chart showing his performance with investors… There is an obvious problem… Read More
Many of the traders I talk to are wondering what Bill Ackman could be thinking. Ackman is a hedge fund manager, the founder and CEO of Pershing Square Capital Management, which has about $11 billion under management. Ackman is considered a contrarian investor who tends to buy when companies are down, and an activist investor who sometimes takes a role in managing companies he invests in. He has achieved incredible success by some measures and has a reported wealth of about $1.4 billion. Ackman recently shared a chart showing his performance with investors… There is an obvious problem with recent performance. As Ackman explained, “The substantial decline in performance from August 2015 through March 31, 2016 is largely due to Valeant’s decline…” Valeant is now the investment traders are talking about. Ackman took a large stake in Valeant Pharmaceuticals International (NYSE: VRX) as the company was growing rapidly through acquisitions. The strategy largely relied on buying other companies and then raising prices, a tactic that we know was widespread in the drug sector. But regulators began to question the strategy after it was discovered VRX was using in-house pharmacists to potentially overbill insurance companies. Traders reacted to the… Read More